PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'SGS Life Sciences, Antwerp, Belgium.\', \'Merck & Co., Inc., Kenilworth, NJ, USA.\', \'Merck & Co., Inc., Kenilworth, NJ, USA; Currently at AlloVir, Inc., Cambridge, MA, USA.\', \'Merck & Co., Inc., Kenilworth, NJ, USA; Currently at Flagship Pioneering, Boston, MA, USA.\', \'Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.\', \'Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: eseng_lai@merck.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S2352-3964(21)00605-810.1016/j.ebiom.2021.103811
?:doi
?:hasPublicationType
?:journal
  • EBioMedicine
is ?:pmid of
?:pmid
?:pmid
  • 35042081
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.895
?:rankingScore_hIndex
  • 26
?:title
  • Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35042081>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35042081>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all